Supplementary Materials

Supplementary Material for:

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Chetan Bettegowda, Mark Sausen, Rebecca J. Leary, Isaac Kinde, Yuxuan Wang, Nishant Agrawal, Bjarne R. Bartlett, Hao Wang, Brandon Luber, Rhoda M. Alani, Emmanuel S. Antonarakis, Nilofer S. Azad, Alberto Bardelli, Henry Brem, John L. Cameron, Clarence C. Lee, Leslie A. Fecher, Gary L. Gallia, Peter Gibbs, Dung Le, Robert L. Giuntoli, Michael Goggins, Michael D. Hogarty, Matthias Holdhoff, Seung-Mo Hong, Yuchen Jiao, Hartmut H. Juhl, Jenny J. Kim, Giulia Siravegna, Daniel A. Laheru, Calogero Lauricella, Michael Lim, Evan J. Lipson, Suely Kazue Nagahashi Marie, George J. Netto, Kelly S. Oliner, Alessandro Olivi, Louise Olsson, Gregory J. Riggins, Andrea Sartore-Bianchi, Kerstin Schmidt, le-Ming Shih, Sueli Mieko Oba-Shinjo, Salvatore Siena, Dan Theodorescu, Jeanne Tie, Timothy T. Harkins, Silvio Veronese, Tian-Li Wang, Jon D. Weingart, Christopher L. Wolfgang, Laura D. Wood, Dongmei Xing, Ralph H. Hruban, Jian Wu, Peter J. Allen, C. Max Schmidt, Michael A. Choti, Victor E. Velculescu,* Kenneth W. Kinzler,* Bert Vogelstein,* Nickolas Papadopoulos,* Luis A. Diaz Jr.

*Corresponding author. E-mail: (L.A.D.); (N.P.); (B.V.); (K.W.K.); (V.E.V.)

Published 19 February 2014, Sci. Transl. Med. 6, 224ra24 (2014)
DOI: 10.1126/scitranslmed.3007094

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Comparison of methods for analysis of point mutations in plasma DNA.
  • Fig. S2. ctDNA in advanced malignancies, ranking of the fraction of patients with detectable ctDNA.
  • Fig. S3. Diagram of the assay used to confirm rearrangements in plasma DNA.
  • References (5258)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1 (Microsoft Excel format). Summary of tissue mutations, plasma mutations, and clinical information for 410 early- and advanced-stage subjects.
  • Table S2 (Microsoft Excel format). Comparison of ctDNA levels assessing point mutations and rearrangements in the same specimens.
  • Table S3 (Microsoft Excel format). Comparison between plasma and tumor tissue KRAS status in 206 patients with metastatic CRC.
  • Table S4 (Microsoft Excel format). Clinical characteristics of patients with discordant tissue and plasma KRAS mutation data.
  • Table S5 (Microsoft Excel format). Clinical characteristics of patients with false negatives in plasma KRAS mutation compared with tissue samples.
  • Table S6 (Microsoft Excel format). Association between clinical characteristics and absolute levels of ctDNA.
  • Table S7 (Microsoft Excel format). Association between clinical characteristics and ctDNA concentration (log scale) in metastatic CRC patients.
  • Table S8 (Microsoft Excel format). Patient characteristics and plasma mutations detected after EGFR blockade.
  • Filename: generate.table.r
  • Filename: Table_S1_analysis.r
  • Filename: Table_S3_analysis.r

[Tables S1 to S8]

[r scripts]